Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients

British Journal of Cancer

Volumn 107, Issue 4, 2012, Pages 588-591

  Wagner, U ^a   Marth, C ^b   Largillier, R ^c   Kaern, J ^d   Brown, C ^e   Heywood, M ^f   Bonaventura, T ^g   Vergote, I ^h   Piccirillo, M C ⁱ   Fossati, R ^j   Gebski, V ^e   Lauraine, E P ^k  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Centre Azureen de Cancerologie   (France)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF SYDNEY   (Australia)

^f Department of Gyn Oncology   (Canada)

^g NEWCASTLE MATER HOSPITAL   (Australia)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^k UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

CALYPSO; carboplatin; overall survival; paclitaxel; pegylated liposomal doxorubicin; platinum sensitive; recurrent ovarian cancer

Indexed keywords

CARBOPLATIN; DOXORUBICIN; PACLITAXEL;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; PLATINUM; POLYETHYLENE GLYCOLS; RECURRENCE; TREATMENT OUTCOME;

EID: 84864879755     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.307     Document Type: Article

References (13)

1. Bafaloukos D, Linardou H, Aravantinos G, Papadimitriou C, Bamias A, Fountzilas G, Kalofonos HP, Kosmidis PE, Makatsoris T, Samantas E, Briasoulis E, Christodoulou C, Papakostas P, Pectasides D, Dimopoulos AM (2010) A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. BMC Med 8: 3
2. Ferrero JM, Weber B, Geay JF, Lepille D, Orfeuvre H, Combe M, Mayer F, Leduc B, Bourgeois H, Paraiso D, Pujade-Lauraine E (2007) Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18: 263-268
3. Gladieff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S (2011) Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial. Ann Oncol 23: 1185-1189
4. González-Martín AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, Ojeda B, Balañá C, Martínez E, Herrero A, Pardo B, Adrover E, Rifá J, Godes MJ, Moyano A, Cervantes A (2005) Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinumsensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) study. Ann Oncol 16: 749-755
5. Gordon A, Fleagle J, Guthrie D, Parkin D, Gore M, Lacave A (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19: 3312-3322
6. Gordon A, Tonda M, Sun S, Rackoff W, Doxil Study 30-49 Investigators (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95: 1-8
7. Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman K, Sugimoto A, Vaughan M, Reinthaller A, Vergote I, Ferrandina G, Dell'Anna T, Huober J, Pujade-Lauraine E (2011) Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trial. Gynecol Oncol 122: 226-232
8. Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E, Gynecologic Cancer Intergroup (2011) Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Ann Oncol 22: 2417-2423
9. Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Mirza MR, Sauthier P, Pujade-Lauraine E, Lord SJ, Simes RJ (2011) Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. J Natl Cancer Inst 103: 1338-1342
10. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C, ICON and AGO Collaborators (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106
11. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E, AGO-OVAR, NCIC CTG, EORTC GCG (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24: 4699-4707
12. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinumsensitive ovarian cancer in late relapse. J Clin Oncol 28: 3323-3329
13. Weber B, Lortholary A, Mayer F, Bourgeois H, Orfeuvre H, Combe M, Platini C, Cretin J, Fric D, Paraiso D, Pujade-Lauraine E (2009) Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial. Anticancer Res 29: 4195-4200